Gola Cecilia, Giannuzzi Diana, Rinaldi Andrea, Iussich Selina, Modesto Paola, Morello Emanuela, Buracco Paolo, Aresu Luca, De Maria Raffaella
Department of Veterinary Science, University of Turin, Turin, Italy.
Department of Agronomy, Food, Natural Resources, Animals, and Environment, University of Padua, Padua, Italy.
Front Vet Sci. 2021 May 17;8:666838. doi: 10.3389/fvets.2021.666838. eCollection 2021.
Osteosarcoma (OSA) represents the most common primary bone tumor in dogs and is characterized by a highly aggressive behavior. Cell lines represent one of the most suitable and reproducible pre-clinical models, and therefore the knowledge of their molecular landscape is mandatory to investigate oncogenic mechanisms and drug response. The present study aims at determining variants, putative driver genes, and gene expression aberrations by integrating whole-exome and RNA sequencing. For this purpose, eight canine OSA cell lines and one matched pair of primary tumor and normal tissue were analyzed. Overall, cell lines revealed a mean tumor mutational burden of 9.6 mutations/Mb (range 3.9-16.8). Several known oncogenes and tumor suppressor genes, such as , and , were prioritized as having a likely role in canine OSA. Mutations in eight genes, previously described as human OSA drivers and including , and , were retrieved in our cell lines. When variants were cross-referenced with human OSA driver mutations, the E273K mutation of was identified in the Wall cell line and tumor sample. The transcriptome profiling detected two possible p53 inactivation mechanisms in the Wall cell line on the one hand, and in D17 and D22 on the other. Moreover, overexpression, potentially leading to MAPK/ERK pathway activation, was observed in D17 and D22 cell lines. In conclusion, our data provide the molecular characterization of a large number of canine OSA cell lines, allowing future investigations on potential therapeutic targets and associated biomarkers. Notably, the Wall cell line represents a valuable model to empower prospective studies both in human and in dogs, since the driver mutation was maintained during cell line establishment and was widely reported as a mutation hotspot in several human cancers.
骨肉瘤(OSA)是犬类最常见的原发性骨肿瘤,具有高度侵袭性。细胞系是最合适且可重复的临床前模型之一,因此了解其分子格局对于研究致癌机制和药物反应至关重要。本研究旨在通过整合全外显子组测序和RNA测序来确定变异、推定的驱动基因和基因表达异常。为此,分析了八个犬OSA细胞系以及一对匹配的原发性肿瘤和正常组织。总体而言,细胞系显示平均肿瘤突变负担为9.6个突变/Mb(范围为3.9 - 16.8)。几个已知的癌基因和肿瘤抑制基因,如 、 和 ,被确定可能在犬OSA中起作用。在我们的细胞系中检索到了八个先前被描述为人类OSA驱动基因的基因突变,包括 、 和 。当将这些变异与人类OSA驱动基因突变进行交叉比对时,在Wall细胞系和肿瘤样本中鉴定出了 的E273K突变。转录组分析一方面在Wall细胞系中检测到了两种可能的p53失活机制,另一方面在D17和D22细胞系中也检测到了。此外,在D17和D22细胞系中观察到 过表达,这可能导致MAPK/ERK通路激活。总之,我们的数据提供了大量犬OSA细胞系的分子特征,有助于未来对潜在治疗靶点和相关生物标志物的研究。值得注意的是,Wall细胞系是一个有价值的模型,可用于加强人类和犬类的前瞻性 研究,因为在细胞系建立过程中维持了 驱动基因突变,并且该突变在几种人类癌症中被广泛报道为突变热点。